The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
NCCN Task Force Report: Oral Chemotherapy
Open accessAbstract
Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral and parenteral therapy is available, patients may opt for oral chemotherapy because it is more convenient to administer, allows them to avoid multiple office visits, and gives them a sense of control over their own cancer care. Whether these potential advantages are maintained in regimens that combine oral and parenteral drugs is less clear. The use of oral chemotherapeutic agents profoundly affects all aspects of oncology, including creating significant safety and adherence issues, shifting some traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers. The financing of chemotherapy is also affected. To address these issues, the NCCN convened a multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy. (JNCCN 2008;6[Suppl 3]:S1–S14)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Long-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Patient preferences for oral versus intravenous palliative chemotherapy.
Liu, G., Franssen, E., Fitch, M. I., & Warner, E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.110 · Cited by 919
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.9.652 · Cited by 584
Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy
Basch, E., Artz, D., Dulko, D., Scher, K., Sabbatini, P., Hensley, M., Mitra, N., Speakman, J., McCabe, M., & Schrag, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.275 · Cited by 310
Basch, E., Iasonos, A., Barz, A., Culkin, A., Kris, M. G., Artz, D., Fearn, P., Speakman, J., Farquhar, R., Scher, H. I., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2243 · Cited by 200
Schneeweiß, S., Patrick, A. R., Maclure, M., Dormuth, C. R., & Glynn, R. J. (2007) · Circulation · doi:10.1161/circulationaha.106.665992 · Cited by 145
Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?
Jacobson, M., O’Malley, A. J., Earle, C. C., Pakes, J., Gaccione, P., & Newhouse, J. P. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.437 · Cited by 136
Oral chemotherapy safety practices at US cancer centres: questionnaire survey
Weingart, S. N., Flug, J. A., Brouillard, D., Morway, L., Partridge, A. H., Bartel, S. B., Shulman, L. N., & Connor, M. (2007) · BMJ · doi:10.1136/bmj.39069.489757.55 · Cited by 110
Self-citationTsang, J., Rudychev, I., & Pescatore, S. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.6119 · Cited by 64
Cited by
Smartphone medication adherence apps: Potential benefits to patients and providers
Dayer, L., Heldenbrand, S., Anderson, P., Gubbins, P. O., & Martin, B. C. (2013) · Journal of the American Pharmacists Association · doi:10.1331/japha.2013.12202 · Cited by 473
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Machiels, J.-P. H., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Vermorken, J. B., Clement, P. M., Gauler, T., Cupissol, D., Grau, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70124-5 · Cited by 394
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Greer, J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0405 · Cited by 344
Krohe, M., Eek, D., Mazar, I., Horsfield, A., Pompilus, F., Friebe, R., & Shields, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106629 · Cited by 265
Lin, C., Clark, R., Tu, P., Bosworth, H. B., & Zullig, L. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4317-2 · Cited by 160
Employment implications of informal cancer caregiving
de Moor, J. S., Dowling, E. C., Ekwueme, D. U., Guy, G. P., Rodriguez, J., Virgo, K. S., Han, X., Kent, E. E., Li, C., Litzelman, K., et al. (2017) · Journal of Cancer Survivorship · doi:10.1007/s11764-016-0560-5 · Cited by 100
Oral lipid nanomedicines: Current status and future perspectives in cancer treatment
El Moukhtari, S. H., Rodríguez-Nogales, C., & Blanco-Prieto, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.004 · Cited by 70
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
Gater, A., Heron, L., Abetz-Webb, L., Coombs, J., Simmons, J., Guilhot, F., & Rea, D. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.01.021 · Cited by 59
Improving the Safety of Oral Chemotherapy at an Academic Medical Center
Shah, N. N., Casella, E., Capozzi, D., McGettigan, S., Gangadhar, T. C., Schuchter, L., & Myers, J. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.007260 · Cited by 33
Mobile-based oral chemotherapy adherence-enhancing interventions: scoping review
Skrabal Ross, X., Gunn, K. M., Patterson, P., & Olver, I. (2018) · JMIR mhealth and uhealth · doi:10.2196/11724 · Cited by 24
Doolin, J. W., Berry, J. L., Forbath, N. S., Tocci, N. X., Dechen, T., Li, S., Hartwell, R. A., Espiritu, J. K., Roberts, D. A., Zerillo, J. A., et al. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00191 · Cited by 20
Dang, T. H., Wickramasinghe, N., Jayaraman, P. P., Burbury, K., Alexander, M., Whitechurch, A., Dyer, M., Quinn, S., Forkan, A. R. M., & Schofield, P. (2025) · JMIR Formative Research · doi:10.2196/65302 · Cited by 9
Metadata
- Authors
- Weingart, S. N., Brown, E., Bach, P. B., Eng, K., Johnson, S. A., Kuzel, T. M., Langbaum, T. S., Leedy, R. D., Muller, R. J., Newcomer, L. N., O’Brien, S., Reinke, D., Rubino, M., Saltz, L., & Walters, R. S.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2008-06
- Volume
- 6
- Issue
- S3
- Pages
- S-1-S-14
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W32006757
- Cited by
- 435
- References
- 14
- FWCI
- 46.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.